Found 7 matching trials
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD) PHASE2 The primary objective of this study is to determine the optimum dose(s) of ...
Show More Location
1237.9.00152 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease PHASE3 The study is intended to characterize the lung function profile of BI1744 i...
Show More Location
1222.25.25009 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD) PHASE2 The primary objective of this study is to determine the optimum dose(s) of ...
Show More Location
1237.4.0118 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers PHASE1 To investigate safety, tolerability, pharmacokinetics and pharmacodynamics ...
Show More Location
Multiple Locations
Learn More & Join Trial
Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma PHASE2 The primary objective of this study is to assess the efficacy (bronchoprote...
Show More Location
1222.4.103 UBC - Respiratory Medicine
Learn More & Join Trial
Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) PHASE2 The primary objective of this study is to determine the optimum once daily ...
Show More Location
1237.18.02004 Boehringer Ingelheim Investigational Site
Learn More & Join Trial
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. PHASE2 The primary objective of this study is to determine the efficacy and safety...
Show More Location
1222.27.43002 Boehringer Ingelheim Investigational Site
Learn More & Join Trial